Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational rollover safety trial of brexpiprazole in agitation associated with dementia of the Alzheimer’s type
2014-000424-23Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brexpiprazole in Alzheimer's disease (AD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Safety outcomes during rollover period. Started Aug 2014; status: completed.
02
Drugs
brexpiprazole
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2014-000424-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000424-23.